Royal Bank Of Canada Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Insulet (NASDAQ:PODD) had its target price increased by Royal Bank Of Canada from $160.00 to $180.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has an outperform rating on the medical instruments supplier’s stock.

Other equities research analysts have also issued reports about the company. Robert W. Baird set a $175.00 price objective on Insulet in a research note on Thursday, August 6th. TD Cowen reiterated a “hold” rating on shares of Insulet in a report on Wednesday. Benchmark cut their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Truist Financial lowered Insulet from a “buy” rating to a “hold” rating and cut their target price for the company from $210.00 to $153.00 in a research report on Wednesday, August 5th. Finally, Citigroup boosted their price target on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Insulet has a consensus rating of “Hold” and a consensus price target of $192.36.

Insulet Stock Down 5.4%

PODD stock opened at $156.12 on Thursday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.83 and a current ratio of 2.51. Insulet has a one year low of $126.40 and a one year high of $354.88. The firm’s fifty day moving average is $141.91 and its 200 day moving average is $177.34. The firm has a market cap of $10.83 billion, a PE ratio of 25.43, a P/E/G ratio of 1.25 and a beta of 1.06.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The company had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. During the same quarter in the prior year, the firm posted $1.24 EPS. Insulet’s quarterly revenue was up 19.2% compared to the same quarter last year. On average, research analysts forecast that Insulet will post 6.76 EPS for the current year.

Institutional Investors Weigh In On Insulet

Several institutional investors have recently added to or reduced their stakes in the business. Elevation Wealth Partners LLC boosted its holdings in shares of Insulet by 115.6% in the 3rd quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 104 shares in the last quarter. Activest Wealth Management grew its stake in Insulet by 186.3% during the 3rd quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 149 shares during the last quarter. WPG Advisers LLC grew its stake in Insulet by 169.3% during the 3rd quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 171 shares during the last quarter. Covestor Ltd boosted its holdings in shares of Insulet by 103.9% in the third quarter. Covestor Ltd now owns 310 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 158 shares during the period. Finally, Jacobi Capital Management LLC acquired a new stake in shares of Insulet in the third quarter valued at approximately $40,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.